AI Summary
This article discusses the impact of CDK4/6 inhibitors in combination with endocrine therapy on overall survival in first-line HR+/HER2- advanced breast cancer. It highlights the significant benefit shown in progression-free survival in pivotal trials, with some trials demonstrating improvements in overall survival as well. The study compares the efficacy of different CDK4/6 inhibitors in this setting.
The introduction of CDK4/6 inhibitors (CDK4/6i) in combination with endocrine therapy (ET) has been a major breakthrough in the treatment of HR+/HER2- advanced breast cancer (ABC). The approval of palbociclib, ribociclib, and abemaciclib in this setting was supported by the consistent benefit of the combination of CDK4/6i with ET in the primary endpoint of the pivotal trials, which was progression-free survival (PFS).1-3 While MONALEESA-2 and MONALEESA-7 also reported a statistically significant improvement in overall survival (OS), differences in OS were not apparent in PALOMA-2.